Literature DB >> 18463380

Tumor angiogenesis.

Robert S Kerbel1.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18463380      PMCID： PMC4542009          DOI： 10.1056/NEJMra0706596

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  99 in total

Review 1.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer.

Authors:  Rakesh K Jain; Dan G Duda; Jeffrey W Clark; Jay S Loeffler
Journal:  Nat Clin Pract Oncol       Date:  2006-01

2.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

3.  Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.

Authors:  Christian Fischer; Bart Jonckx; Massimiliano Mazzone; Serena Zacchigna; Sonja Loges; Lucia Pattarini; Emmanuel Chorianopoulos; Laurens Liesenborghs; Marta Koch; Maria De Mol; Monica Autiero; Sabine Wyns; Stephane Plaisance; Lieve Moons; Nico van Rooijen; Mauro Giacca; Jean-Marie Stassen; Mieke Dewerchin; Desire Collen; Peter Carmeliet
Journal:  Cell       Date:  2007-11-02       Impact factor: 41.582

Review 4.  Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis?

Authors:  Richard C A Sainson; Adrian L Harris
Journal:  Trends Mol Med       Date:  2007-09-06       Impact factor: 11.951

Review 5.  The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth.

Authors:  Gavin Thurston; Irene Noguera-Troise; George D Yancopoulos
Journal:  Nat Rev Cancer       Date:  2007-05       Impact factor: 60.716

6.  Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy.

Authors:  Patrizia Mancuso; Marco Colleoni; Angelica Calleri; Laura Orlando; Patrick Maisonneuve; Giancarlo Pruneri; Alice Agliano; Aron Goldhirsch; Yuval Shaked; Robert S Kerbel; Francesco Bertolini
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

7.  Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.

Authors:  Guido Bocci; Shan Man; Shane K Green; Giulio Francia; John M L Ebos; Jeanne M du Manoir; Adina Weinerman; Urban Emmenegger; Li Ma; Philip Thorpe; Andrew Davidoff; James Huber; Daniel J Hicklin; Robert S Kerbel
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

8.  VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism.

Authors:  Hans-Peter Gerber; Ajay K Malik; Gregg P Solar; Daniel Sherman; Xiao Huan Liang; Gloria Meng; Kyu Hong; James C Marsters; Napoleone Ferrara
Journal:  Nature       Date:  2002-06-27       Impact factor: 49.962

9.  Tumor induction of VEGF promoter activity in stromal cells.

Authors:  D Fukumura; R Xavier; T Sugiura; Y Chen; E C Park; N Lu; M Selig; G Nielsen; T Taksir; R K Jain; B Seed
Journal:  Cell       Date:  1998-09-18       Impact factor: 41.582

10.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.

Authors:  L E Benjamin; D Golijanin; A Itin; D Pode; E Keshet
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808
View more
  826 in total

1.  A pilot study of bevacizumab and interferon-α2b in ocular melanoma.

Authors:  Kristan D Guenterberg; Valerie P Grignol; Kiran V Relekar; Kimberly A Varker; Helen X Chen; Kari L Kendra; Thomas E Olencki; William E Carson
Journal:  Am J Clin Oncol       Date:  2011-02       Impact factor: 2.339

Review 2.  Antiangiogenic therapies for glioblastoma.

Authors:  Isabel Arrillaga-Romany; Andrew D Norden
Journal:  CNS Oncol       Date:  2014

Review 3.  Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.

Authors:  S A Kono; L E Heasley; R C Doebele; D R Camidge
Journal:  Curr Cancer Drug Targets       Date:  2012-02       Impact factor: 3.428

Review 4.  Evaluation of treatment response in patients with metastatic renal cell carcinoma: role of state-of-the-art cross-sectional imaging.

Authors:  Venkata S Katabathina; Nathalie Lassau; Ivan Pedrosa; Chaan S Ng; Srinivasa R Prasad
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

5.  Host-derived pericytes and Sca-1+ cells predominate in the MART-1- stroma fraction of experimentally induced melanoma.

Authors:  J Humberto Treviño-Villarreal; Douglas A Cotanche; Rosalinda Sepúlveda; Magda E Bortoni; Otto Manneberg; Taturo Udagawa; Rick A Rogers
Journal:  J Histochem Cytochem       Date:  2011-12       Impact factor: 2.479

Review 6.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

Review 7.  Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.

Authors:  Thomas Schmidt; Isabel Ben-Batalla; Alexander Schultze; Sonja Loges
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 8.  Practicing pathology in the era of big data and personalized medicine.

Authors:  Jiang Gu; Clive R Taylor
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014-01

9.  Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies.

Authors:  Larissa Sweeny; Andrew Prince; Neel Patel; Lindsay S Moore; Eben L Rosenthal; Brian B Hughley; Jason M Warram
Journal:  Laryngoscope       Date:  2016-08-31       Impact factor: 3.325

10.  Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

Authors:  Teresa Troiani; Erika Martinelli; Floriana Morgillo; Anna Capasso; Anna Nappi; Vincenzo Sforza; Fortunato Ciardiello
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.